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Background: Methotrexate (MTX) is standard treatment for RA. Absorption is better in subcutaneous MTX (scMTX),
which may impact speed of onset. In RA, earlier time to remission improves long-term results. Our objectives were
to determine rapidity of response of subcutaneous methotrexate in early rheumatoid arthritis.
Methods: The change in several disease activity measures (including DAS28) from 0 to 6 weeks (early period) and 6
to 12 weeks (late period) was compared. The proportion achieving DAS28/CDAI/SDAI remission and/or low disease
activity state was also compared.
Results: One hundred three patients were included from a single site between 2008 and 2014. All received MTX
(98.0 % scMTX, 98 % 25 mg/week). There were no dropouts. There was a significantly greater early change in
DAS28 (−1.9 vs. −0.2, p < 0.00); this effect was seen for several outcome measures. By 6 weeks, 59 % had achieved
either DAS28 remission or low disease activity state, with 74 % achieving either state by 12 weeks.
There were a larger proportion of patients achieving CDAI and DAS28 remission in the early versus late period
(p < 0.0002 for both). There was significant improvement when using combination MTX and HCQ, however sample
size was small (n = 9). The use of intra-articular steroids with MTX yielded the most disease measures that
demonstrated early significant improvement.
Conclusion: Subcutaneous MTX is rapid, as the change in many disease activity scores was significantly greater
between 0–6 weeks compared to 6–12 weeks. Combination MTX + HCQ gave added value, although generalizability is
limited by combination cohort sample size. Intra-articular steroid injections may contribute to the early effect.
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Rheumatoid arthritis (RA) is a chronic autoimmune in-
flammatory disease characterized by joint swelling, pain
that can lead to joint damage, functional impairment,
disability, deterioration of quality of life, and premature
mortality [1–3]. Initiating treatment for RA early in the
disease process can lead to improved long-term out-
comes, suggesting that there is an optimal window of
opportunity for achieving treatment targets [2, 4–6].
Despite the existence of newer anti-rheumatic drugs
(disease modifying anti-rheumatic drugs; DMARDs),
methotrexate (MTX) remains the most widely used
DMARD because it is effective, has an acceptable tox-
icity profile, and inexpensive [7–11]. Dosing and route
of MTX administration have evolved. Early trials started
with low doses (5–7.5 mg/week); however, modern prac-
tice typically involves starting at or rapidly escalating to
higher doses (15–25 mg/week) for optimal outcomes
[12–15]. Route of MTX delivery may also impact disease
outcomes; bioavailability is higher when given subcuta-
neously (sc), possibly relating to limitations in gas-
trointestinal tract absorption and patient adherence
secondary to GI side effects [12, 13]. A previous study of
oral and sc MTX in patients with RA suggested that oral
administration was less effective [12]. A separate obser-
vational study demonstrated a significant association be-
tween initial sc administration of MTX and treatment
continuation over the first year compared to oral MTX
in patients with early RA [13].
The kinetics of optimal initial dosing with subcutaneous
methotrexate are unclear. Methotrexate has traditionally
been considered slow acting, especially in comparison to
newer biologic therapies, with recommendations to re-
assess clinical response to MTX at 12 weeks [7]. However,
this has not been our clinical impression with parenteral
MTX. The objective of this study was to determine the
kinetics of optimizing initial dosing with sc MTX in pa-
tients with early rheumatoid arthritis, comparing outcomes
at 6 and 12 weeks after initiation of methotrexate with or
without other treatment such as intra-articular steroids.
Methods
Study design
Data were collected retrospectively from a single site in-
ception cohort of patients enrolled into the Canadian
Early Arthritis Cohort (CATCH) study. CATCH is an ob-
servational, prospective “real world” cohort of patients
with early inflammatory arthritis (EIA) recruiting at 15
sites since July 2007. Inclusion criteria were: age >16 years,
between 6 weeks and 12 months of persistent synovitis at
time of entry, and ≥ 2 swollen joints or 1 swollen metacar-
pophalangeal or proximal interphalangeal joint and ≥ 1 of
the following were required: positive rheumatoid factor
(RF), positive anti-cyclic citrullinated peptide (anti-CCP),morning stiffness >45 min, response to nonsteroidal
anti-inflammatory drugs, or painful metatarsophalangeal
squeeze test. Outcomes are collected at each visit includ-
ing global assessments, joint counts, and inflammatory
markers. Treatment was left to the discretion of the
treating physician and included: monotherapy or combin-
ation DMARD therapy, steroids, NSAIDs and biologics.
CATCH patients enrolled at a single site (Southlake
Regional Health Centre) were included if they: attended
an additional “early follow-up” appointment 6 ± 2 weeks
from baseline, attended a 12-week follow up appointment,
were prescribed methotrexate within 3 months from their
baseline appointment, and were on methotrexate at least
1 month between baseline and the 6 ± 2 week follow-up
appointment. At early follow-up, the standard CATCH
protocol was used to evaluate patients. Data from early
follow-up were collected from paper and/or electronic
records as this visit was not part of the standard CATCH
protocol. One individual (HK) was responsible for data
collection and coding.
Disease measures assessed at baseline, 6 and 12 weeks
included: swollen joint count (SJC), 28-tender joint count
(TJC28), 28-swollen joint count (SJC28), 28-joint disease
activity score (DAS28ESR, DAS28CRP), sleep, pain, fa-
tigue, physician global assessment, patient global assess-
ment, health assessment questionnaire (HAQ), ESR, and
CRP. Other composite scores were calculated, including
the clinical disease activity index (CDAI) and simplified
disease activity index (SDAI). Data regarding tolerability
to methotrexate were also collected, including incidence
of headache, nausea, and gastrointestinal side effects.
Statistical methods
A repeated measures ANOVA was performed to
compare each disease activity score at baseline, 6 and
12 weeks. A repeated measures ANOVA was also per-
formed on the calculated mean difference in disease ac-
tivity scores between baseline and 6 weeks, 6 and
12 weeks, and baseline and 12 weeks. A paired t-test was
performed to compare the mean difference in disease ac-
tivity scores between early (baseline to 6 weeks) and late
(6–12 weeks) groups.
Subgroup analyses assessed the effect of confounding
concomitant steroid use and combination therapy with
HCQ. Patients were classified according to route of ster-
oid use: intra-articular, oral, intra-muscular, combin-
ation, and no steroid. A repeated-measures ANOVA
compared raw disease activity scores and the mean dif-
ference between time points. Post hoc analysis compared
mean scores between early (baseline to 6 weeks) and late
(6–12 weeks) groups across routes of steroid use. A
similar analysis was performed to compare scores in pa-
tients receiving monotherapy versus combination ther-
apy with HCQ.
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Patient population
A total of 103 of 209 CATCH patients enrolled at the
single site were included. The mean age was 56.2 years
(SD 16.0), with 64 % female (Fig. 1 and Table 1). Almost
all (98 %) were on subcutaneous methotrexate, and 2 %
on oral methotrexate. Mean symptom duration at first
visit was 159 days (SD 106), and 83 % met 2010 ACR/
EULAR criteria for rheumatoid arthritis. More than half
(59 %) were rheumatoid factor positive. Majority (57 %)
were ever-smokers, 85 % Caucasian, 61 % married, and
56 % had post-secondary education. Half were employed,
and 54 % had an income between $20,000 and $100,000.
The mean number of concomitant comorbidities was 3.0
(SD 2.4). There were no statistically significant differ-
ences in patient demographics between those who
attended early follow-up (103) and those who did notFig. 1 Patient disposition(37). Anti-CCP was not collected consistently due to
lack of universal funding coverage for test, and thus is
not reported.
Remission and low disease-activity state
The proportion of patients in newly achieving either re-
mission or low disease-activity state as per CDAI, SDAI
and DAS28 scores are shown in Table 2. At baseline,
66 % of patients were classified as CDAI high disease ac-
tivity state, with 9 % in LDA state. By 6 weeks, 17 % had
achieved CDAI remission with an additional 1 % achiev-
ing CDAI remission by 12 weeks; there were a larger
proportion of patients entering into early CDAI remis-
sion (16 %) versus later remission (1 %) (p < 0.0002).
Similar results were found for DAS28 remission
(Table 2). By 6 weeks, 59 % had achieved either DAS28
remission or low disease activity state, with 74 %
Table 1 Patient demographics of entire cohort, those with 6-week follow-up and those without
Variables All Patients 6 week follow up visit No 6 week follow up visit p value
Mean Values (SD)
N 140 103 37
Female, no. (%) 86 (61.4) 64 (62.1) 22 (59.5) 0.96
Age, mean (SD) (years) 55.78 (15.69) 56.23 (15.98) 54.54 (13.00) 0.86
Meets 2010 ACR/EULAR Criteria, no. (%) 113 (80.7) 85 (82.5) 28 (75.7) 0.90
Mean symptom duration (days) at first visit, mean (SD) 160.24 (107.37) 158.76 (105.48) 164.35 (114.56) 0.96
Rheumatoid Factor positive, no. (%) 156 (58.6) 58 (58.6) 20 (58.8) 0.77
Smoking Status, no. (%)
Current smoker 19 (13.6) 14 (13.6) 5 (13.5) 0.70
Ex-smoker 64 (45.7) 45 (43.7) 19 (51.4)
Never 57 (40.7) 44 (42.7) 13 (35.1)
Caucasian, no. (%) 117 (83.6) 87 (84.5) 30 (81.1) 0.85
Marital status, no. (%)
Single 22 (15.7) 18 (17.5) 4 (10.8) 1.00
Common Law 6 (4.3) 5 (4.9) 1 (2.7)
Married 91 (65.0) 63 (61.2) 28 (75.7)
Education, no. (%)
Elementary school 6 (4.3) 5 (4.9) 1 (2.7) 0.92
High school 56 (40.0) 40 (38.8) 16 (43.2)
College/Trade school 41 (29.3) 27 (26.2) 14 (37.8)
University Bachelor 25 (17.9) 22 (21.4) 3 (8.1)
Masters 7 (5.0) 6 (5.8) 1 (2.7)
PhD 5 (3.6) 3 (2.9) 2 (5.4)
Income, no. (%)
None 6 (4.3) 5 (4.9) 1 (2.7) 0.80
< $20,000 21 (15.0) 17 (16.5) 4 (10.8)
$20,000–$50,000 46 (32.9) 28 (27.2) 18 (48.6)
$50,000–$100,000 36 (25.7) 28 (27.2) 8 (21.6)
> $100,000 10 (7.1) 8 (7.8) 2 (5.4)
Do Not Wish to Answer 21 (15.0) 17 (16.5) 4 (10.8)
Employment, no. (%)
Employed 69 (49.3) 51 (49.5) 18 (48.6) 0.66
Retired 43 (30.7) 31 (30.1) 12 (32.4)
Homemaker 10 (7.1) 6 (5.8) 4 (10.8)
Student 6 (4.3) 5 (4.9) 1 (2.7)
Disabled 4 (2.9) 2 (1.9) 2 (5.4)
Sick Leave 3 (2.1) 3 (2.9) 0 (0)
Maternity Leave 1 (0.7) 1 (1.0) 0 (0)
Unemployed 4 (2.9) 4 (3.9) 0 (0)
Number comorbidities present, mean (SD) 3.03 (2.32) 2.99 (2.38) 3.13 (2.21) 0.95
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proportion of patients that achieved DAS28 remission in
the early vs. late periods (p < 0.00002).Disease activity at early follow-up
Mean change in disease activity scores at each appoint-
ment are presented in Additional file 1. Every disease
Table 2 The proportion of patients in CDAI/SDAI/DAS28 remission, low activity, moderate activity and high activity states at 0, 6 and
12 weeks. CDAI: Clinical Disease Activity Index; SDAI: Simplified Disease Activity Index; DAS28: Disease Activity Score in 28 joints
(using ESR)
Remission score Baseline No. (%) 6 weeks No. (%) 12 weeks No. (%) Early (0–6 weeks) vs.
Late (6–12 weeks) (p)
CDAI N 102 96 89
Remission ( ≤ 2.8) 0 (0.0) 16 (16.7) 17 (19.1) 0.0002
Low Activity (2.9–10.0) 9 (8.8) 25 (26.0) 48 (53.9) 0.15
Moderate Activity (10.1–22.0) 26 (25.5) 37 (38.5) 21 (23.6)
High Activity ( > 22) 67 (65.7) 18 (18.8) 3 (3.4)
SDAI N 97 58 37
Remission ( ≤ 3.3) 0 (0.0) 4 (6.9) 3 (8.1)
Low Activity (3.4–11.0) 3 (3.1) 13 (22.4) 16 (43.2) 0.08
Moderate Activity (11.1–26) 15 (15.5) 19 (32.8) 13 (35.1)
High Activity (≥ 26) 79 (81.4) 22 (37.9) 5 (13.5)
DAS28 N 94 85 76
Remission ( ≤ 2.4) 2 (2.1) 22 (25.9) 23 (30.3) 0.00002
Low Activity (2.5–3.6) 9 (9.6) 28 (32.9) 33 (43.4) 0.41
Moderate Activity (3.7–5.5) 40 (42.6) 29 (34.1) 19 (25.0)
High Activity (≥ 5.5) 43 (45.7) 6 (7.1) 1 (1.3)
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and 6 weeks, there was a significant difference in mean
score for all measures except ESR. Between 6 and
12 weeks, there was a significant difference for all mea-
sures except physician global assessment (p = 0.052), CRP
(p = 0.37), DAS28ESR (p = 0.292), and SDAI (p = 0.17).
Between baseline and 12 weeks, there was a significant
change in mean scores for all outcomes. Compared to the
later period (6–12 weeks), there was a significantly greater
early improvement for SJC, SJC28, pain, fatigue, sleep, pa-
tient global assessment, physician global assessment, CRP,
DAS28ESR, DAS28CRP, CDAI and SDAI.
Methotrexate monotherapy vs. combination DMARD
therapy
Of 103 patients included, 94 patients were on metho-
trexate monotherapy and only 9 patients were on
combination therapy with hydroxychloroquine. Within
monotherapy or combination therapy groups, all disease
activity measures significantly differed at each time point
(p ≤ 0.001 for TJC, SJC, TJC28, SJC, pain, fatigue, sleep,
patient global assessment, HAQ, physician global
assessment, CRP, DAS28ESR, DAS28CRP, CDAI, SDAI;
p < 0.02 for ESR). Patients treated with MTX monother-
apy demonstrated a significantly greater early improve-
ment for SJC, SJC28, pain, fatigue, sleep, PTGA, HAQ,
MDGA, DAS28ESR, DAS28CRP, CDAI, and SDAI (all
p ≤ 0.001). In the small cohort of patients on combin-
ation with HCQ (n = 9), there was a non-significant
trend toward greater early improvement.Concomitant steroid use
Of the 103 patients included, 22 patients did not receive
steroids, 15 received oral steroids, 34 received intra-
articular steroids only, 13 received intra-muscular steroids
only, and 19 patients received combination steroids of at
least two routes. Mean disease activity scores at each time
point did not significantly differ between steroid groups.
The patient group treated with intra-articular steroids
alone yielded the highest number of disease measures that
demonstrated significant early improvement. Within the
small cohort treated with combination steroids (n = 19)
there was significant early improvement for only two dis-
ease measures- fatigue (p < 0.001) and PTGA (p < 0.001)
but this group was likely underpowered. In the cohort not
given steroids, there was significant early improvement for
TJC and PTGA (p < 0.03), as well as MDGA, DAS28ESR
and CDAI (all p < 0.02).
Side effects and tolerability
There were no dropouts secondary to methotrexate in-
tolerance over the first 3 months. Few reported headache
(3 %), nausea (4 %), and gastrointestinal symptoms (1 %).
Discussion
Our study demonstrated an early effect of optimal dos-
ing of scMTX in patients with early RA, with signifi-
cantly larger early improvement in several disease
activity scores and higher proportion achieving early
CDAI and DAS28 remission.. Use of concomitant intra-
articular steroid yielded the highest number of disease
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small cohort of patients on combination MTX and HCQ
trended toward a greater degree of early improvement,
however statistical significance was not achieved - likely
secondary to small sample size. Unlike some practices,
we often initiate optimal dosing of MTX at the onset of
treatment instead of escalating over time. This could
contribute to the rapid kinetics of MTX.
Previous data published on MTX therapy in patients
with early rheumatoid arthritis have typically used
12 weeks as the initial follow-up point [7]. In this study,
the kinetics of sc MTX are more rapid. Many of the
patients received concomitant steroids which may facili-
tate a rapid response, but do not necessarily contribute
to the sustained response. Although patients receiving
either oral, intramuscular or intra-articular steroids had
a higher number of disease activity measures that dem-
onstrated significant early improvement, the cohort of
patients who did not receive steroids still demonstrated
significant early improvement for five disease activity
measures.
Although all patients were from a single centre, base-
line characteristics were similar for patients who had
6 weeks visit versus those who did not. This site had
baseline demographic data that were not different from
the overall CATCH cohort [2]. Assessing patients from a
single centre allowed for consistent education, disease
scoring and follow-up protocols. There were few pa-
tients lost to follow-up and little missing data, avoiding
selection bias.
The use of combination therapy with HCQ was also
assessed as another potential confounder. Patients who
initially received combination therapy had significantly
higher disease activity scores at each time point, as com-
pared to those receiving MTX monotherapy, suggesting
that patients in the combination group had more active
RA at presentation. No disease activity measures within
the combination MTX +HCQ group demonstrated a
more significant improvement in the early period com-
pared to the later period, likely due to the small N. We
could not study oral MTX as it was too rarely used in
this practice and there was no triple therapy. The lack of
a control group is problematic for the interpretation of
the results (po MTX), lack of randomization and pre-
scribing biases of steroid use. The relatively low DAS28
in the ERA incident cohort at onset would tend to give
less of a change in DAS28 compared to starting at
higher disease activity. Despite these limitations, there is
no doubt that even when stratifying by steroid use, there
is an early rapid response in those starting optimal doses
of sc MTX. A sub-analysis from the TEAR trial showed
that even with MTX monotherapy or triple therapy, re-
sponse at 12 weeks was predictive of future low disease
activity, but this study did not look at 6 weeks response[16]. Certainly MTX seems to have a larger effect early
(first 6 weeks) compared to the 2nd 6 weeks so perhaps
future response can be predicted even earlier with
optimal dosing of sc MTX.
Conclusions
We found that optimal initial dosing with sc MTX in pa-
tients with early RA was well-tolerated and yielded rapid
(within 6 weeks) significant improvement in many dis-
ease measures, including achieving remission and low
disease activity state. The use of intra-articular steroids
enhanced rapid clinical improvement, as compared to
use of steroids via other routes. Future multicenter stud-
ies are needed to further assess the rapid kinetics of
MTX therapy.
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Additional file 1: Comparison of mean change in outcome
measurement scores between early period (0–6 weeks) and late period
(6–12 weeks). DAS28ESR: Disease Activity Score in 28 joints (using ESR);
TJC28: Tender Joint Count in 28 joints; SJC28: Swollen Joint Count in 28
joints; PTGA: Patient Global Assessment; HAQ: Health Assessment
Questionnaire Disability Index; MDGA: Physician Global Assessment; ESR:
Erythrocyte Sedimentation Rate; CRP: C-Reactive Protein; DAS28CRP: Disease
Activity Score in 28 joints (using CRP); CDAI: Clinical Disease Activity Index;
SDAI: Simplified Disease Activity Index. (PDF 84 kb)
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